Telix Pharmaceuticals Limited
TLPPF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 3.57 | 0.21 | -3.18 | -0.18 |
| FCF Yield | 0.31% | -0.14% | 0.32% | 0.09% |
| EV / EBITDA | 629.57 | 102.69 | 152.76 | 137.55 |
| Quality | ||||
| ROIC | 1.73% | 4.62% | 2.80% | 8.28% |
| Gross Margin | 48.62% | 64.92% | 65.56% | 79.50% |
| Cash Conversion Ratio | -7.74 | -0.81 | 2.88 | 0.54 |
| Growth | ||||
| Revenue 3-Year CAGR | 453.26% | 428.74% | 438.93% | 464.69% |
| Free Cash Flow Growth | 254.24% | -154.82% | 601.16% | -72.29% |
| Safety | ||||
| Net Debt / EBITDA | 23.70 | -1.68 | -2.40 | -4.60 |
| Interest Coverage | 4.03 | 4.14 | 2.78 | 36.63 |
| Efficiency | ||||
| Inventory Turnover | 8.65 | 5.46 | 2.11 | 3.34 |
| Cash Conversion Cycle | 14.79 | 10.89 | 58.08 | -3.51 |